Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 64.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,440 shares of the biopharmaceutical company’s stock after purchasing an additional 43,287 shares during the period. Assenagon Asset Management S.A. owned approximately 0.19% of Agios Pharmaceuticals worth $3,006,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of AGIO. AQR Capital Management LLC boosted its position in shares of Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 20,625 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Agios Pharmaceuticals by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after acquiring an additional 2,920 shares in the last quarter. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals in the first quarter worth approximately $40,000. Goldman Sachs Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares during the period. Finally, Woodline Partners LP acquired a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $597,000.

Agios Pharmaceuticals Price Performance

AGIO opened at $29.61 on Tuesday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The business has a 50-day moving average of $28.33 and a 200-day moving average of $32.19. The company has a market capitalization of $1.73 billion, a PE ratio of -4.16 and a beta of 0.89.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,872 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $27.02, for a total value of $77,601.44. Following the completion of the sale, the insider directly owned 34,793 shares in the company, valued at $940,106.86. The trade was a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Krishnan Viswanadhan sold 2,959 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares of the company’s stock, valued at $142,919.80. This represents a 36.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on AGIO shares. Citigroup upped their price target on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Bank of America boosted their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. Truist Financial increased their target price on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. JPMorgan Chase & Co. raised their target price on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Finally, Leerink Partners lifted their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, December 26th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $40.67.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.